核准了3个CAR-T疗法和1个双型抗体用于膀胱淋巴瘤,表明正在取得进展。 3 CAR-T therapies and 1 bispecific antibody approved for follicular lymphoma, signaling ongoing advancements.

随着CAR-T疗法和双体抗体的引进,胎儿淋巴瘤的治疗环境正在发生变化。 The treatment landscape for follicular lymphoma is evolving with the introduction of CAR-T therapies and bispecific antibodies. 三个CAR-T备选方案,包括YescARTA、BREYANZI和KYMRIAH,已经获得核准,而LUNSUMIO是第一批经核准的复发/耐药性病例的双人专用抗体。 Three CAR-T options, including YESCARTA, BREYANZI, and KYMRIAH, have gained approval, while LUNSUMIO stands out as the first approved bispecific antibody for relapsed/refractory cases. 这些疗法在无障碍和安全方面提供各种好处。 These therapies offer varying benefits in accessibility and safety. 这两种治疗类型的持续进展预示着与这种缓慢增长的癌症作斗争的病人有希望的未来。 Ongoing advancements in both treatment types signal a promising future for patients battling this slow-growing cancer.